tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MREO Stock Latest News

Mereo BioPharma price target raised to $8 from $7 at JPMorgan
The FlyMereo BioPharma price target raised to $8 from $7 at JPMorgan
5d ago
MREO
Mereo Biopharma Group Plc: Strategic Advancements and Promising Developments Justify Buy Rating
PremiumRatings
Mereo Biopharma Group Plc: Strategic Advancements and Promising Developments Justify Buy Rating
14d ago
MREO
Promising Future for Mereo Biopharma: Buy Rating Backed by Positive Trial Prospects and Strong Market Position
PremiumRatings
Promising Future for Mereo Biopharma: Buy Rating Backed by Positive Trial Prospects and Strong Market Position
17d ago
MREO
Mereo BioPharma Reports Increased Losses Amid Strategic Focus
PremiumCompany Announcements
Mereo BioPharma Reports Increased Losses Amid Strategic Focus
17d ago
MREO
Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Strong Financial Position and Promising Study Results
PremiumRatings
Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Strong Financial Position and Promising Study Results
17d ago
MREO
Mereo BioPharma reports Q2 EPS (2c), consensus (1c)
PremiumThe FlyMereo BioPharma reports Q2 EPS (2c), consensus (1c)
17d ago
MREO
Mereo BioPharma sees cash runway into 2027
Premium
The Fly
Mereo BioPharma sees cash runway into 2027
17d ago
MREO
Mereo BioPharma’s Setrusumab Study: A Potential Breakthrough for Osteogenesis Imperfecta
Premium
Company Announcements
Mereo BioPharma’s Setrusumab Study: A Potential Breakthrough for Osteogenesis Imperfecta
21d ago
MREO
Mereo BioPharma’s Setrusumab Study Update: Implications for Investors
PremiumCompany Announcements
Mereo BioPharma’s Setrusumab Study Update: Implications for Investors
1M ago
MREO
Trump declares 50% tariff on copper, Brazil: Morning Buzz
PremiumThe Fly
Trump declares 50% tariff on copper, Brazil: Morning Buzz
2M ago
F
BE
Mereo BioPharma price target lowered to $5 from $7 at Needham
PremiumThe Fly
Mereo BioPharma price target lowered to $5 from $7 at Needham
2M ago
MREO
Mereo BioPharma’s Phase 3 Study Progresses Smoothly
PremiumCompany Announcements
Mereo BioPharma’s Phase 3 Study Progresses Smoothly
2M ago
8K
MREO
Mereo Biopharma Group Plc: Buy Rating Maintained Amid Challenges and Promising Study Outcomes
PremiumRatingsMereo Biopharma Group Plc: Buy Rating Maintained Amid Challenges and Promising Study Outcomes
2M ago
MREO
Promising Outlook for Mereo Biopharma’s Setrusumab Amid Phase 3 Trial Advances and Market Potential
Premium
Ratings
Promising Outlook for Mereo Biopharma’s Setrusumab Amid Phase 3 Trial Advances and Market Potential
2M ago
MREO
Closing Bell Movers: Ultragenyx slumps 25% on UX143 recommendation
Premium
The Fly
Closing Bell Movers: Ultragenyx slumps 25% on UX143 recommendation
2M ago
KLG
MEI
Ultragenyx, Mereo BioPharma receive DMC recommendation to continue Orbit study
PremiumThe Fly
Ultragenyx, Mereo BioPharma receive DMC recommendation to continue Orbit study
2M ago
MREO
RARE
Positive Buy Rating for Mereo Biopharma Driven by Promising Setrusumab Developments and Market Potential
PremiumRatings
Positive Buy Rating for Mereo Biopharma Driven by Promising Setrusumab Developments and Market Potential
2M ago
MREO
Optimistic Buy Rating for Mereo Biopharma Group Plc Driven by Setrusumab’s Potential and Market Opportunities
PremiumRatings
Optimistic Buy Rating for Mereo Biopharma Group Plc Driven by Setrusumab’s Potential and Market Opportunities
3M ago
MREO
Promising Developments and Strategic Positioning Boost Mereo Biopharma’s Prospects
PremiumRatings
Promising Developments and Strategic Positioning Boost Mereo Biopharma’s Prospects
3M ago
MREO
Mereo BioPharma management to meet with BTIG
PremiumThe FlyMereo BioPharma management to meet with BTIG
3M ago
MREO
Buy Rating for Mereo Biopharma Group Plc: Strategic Positioning and Promising Developments in Osteogenesis Imperfecta Treatment
Premium
Ratings
Buy Rating for Mereo Biopharma Group Plc: Strategic Positioning and Promising Developments in Osteogenesis Imperfecta Treatment
3M ago
MREO
Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Promising Lead Programs and Strong Financial Position
Premium
Ratings
Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Promising Lead Programs and Strong Financial Position
4M ago
MREO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >